Dublin, Feb. 02, 2017 -- Research and Markets has announced the addition of the "Closed Drug Transfer Systems to 2022" report to their offering.
The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers.
Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues. Studies of nurses who work with cytotoxic drugs on a regular basis have found a statistically higher rate of spontaneous abortion. Several companies are responding to this unmet need by commercializing devices for closed transfer of these drugs. As the market evolves and user acceptance increases, so too will the impact of these products on oncology therapy protocols and drug delivery
Highlights
- Analyzes the impact of drug toxicity and safety factors on therapeutic oncology market segments, market dynamics and market demographics
- Provides detailed analysis of closed drug transfer products for the handing of cytotoxic drugs
- Analyzes demand drivers and competitive factors influencing closed drug transfer adoption
- Charts product data and provides forecasts to 2022
- Profiles closed drug transfer device participants, their product development activities, business strategies, and corporate alliances and affiliations
Key Topics Covered:
1. Executive Summary
2. Cytotoxic Drug Therapeutics Market Dynamics
- Therapeutic Trends and Issues
- The Administration of injectable/Infusible Antineoplastics
- Drug Packaging and Administration Technology
- Closed Drug Transfer Market Drivers
- Competitive Landscape
- Risk Factors
3. Closed Drug Transfer Design Factors
- Key System Design Elements
- Human Engineering/Ergonomics
- Material Selection Issues
- Drug Reconstitution and Dilution
- Oncology Therapeutics Medication Safety
- Oncology Drug Administration and Dosing
- Drug-Specific Dosing Modification and Individualized Dosing
4. Closed Drug Transfer - Commercial Device Assessments
5. Market Factors
6. Regulatory Issues
- Caregiver Compliance
- Level of Complexity and Ease of Use
- Healthcare Economics
- Business Models and Strategies
7. Market Assessments and Forecasts
8. North America
- Europe
- Asia
- Other Geographic Markets
9.Closed Drug Transfer - Market Participant Profiles
For more information about this report visit http://www.researchandmarkets.com/research/fdrxr6/closed_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 



